These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27815067)

  • 21. [Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].
    Streinu-Cercel A; Ion DA; Chivu LI; Chivu RD
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):521-5. PubMed ID: 17571539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The experts speak. Metabolic complications associated with HIV infection and antiretroviral therapy. Interview by Vicki Glaser.
    Powderly W
    AIDS Patient Care STDS; 2004 Aug; 18(8):431-5. PubMed ID: 15321014
    [No Abstract]   [Full Text] [Related]  

  • 23. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
    Fantoni M; Del Borgo C; Autore C; Barbaro G
    Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current treatment methods for combination antiretroviral therapy-induced lipoatrophy of the face.
    Kadouch JA; van Rozelaar L; Karim RB; Hoekzema R
    Int J STD AIDS; 2013 Sep; 24(9):685-94. PubMed ID: 23970569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What should we know about metabolic syndrome and lipodystrophy in AIDS?
    Signorini DJ; Monteiro MC; Andrade Mde F; Signorini DH; Eyer-Silva Wde A
    Rev Assoc Med Bras (1992); 2012; 58(1):70-5. PubMed ID: 22392319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV.
    Boehme RE; Cameron S
    Antivir Ther; 2009; 14(8):1195-208. PubMed ID: 20032550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options.
    Mallewa JE; Wilkins E; Vilar J; Mallewa M; Doran D; Back D; Pirmohamed M
    J Antimicrob Chemother; 2008 Oct; 62(4):648-60. PubMed ID: 18565973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prevalence of metabolic complications after 10 years of antiretroviral treatment in Senegal].
    Diouf A; Cournil A;
    Bull Soc Pathol Exot; 2014 Oct; 107(4):234-7. PubMed ID: 24683016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiretroviral therapy: new solutions bring new problems.
    Atkins JL; Eccles S; Butler PE
    BMJ; 2003 Feb; 326(7384):337. PubMed ID: 12574054
    [No Abstract]   [Full Text] [Related]  

  • 30. Targets of metabolic toxicity of HIV antiretroviral drugs: the multiple roads to lipodystrophy and metabolic syndrome.
    Domingo P; Villarroya F
    Curr Pharm Des; 2010 Oct; 16(30):3337-8. PubMed ID: 20687885
    [No Abstract]   [Full Text] [Related]  

  • 31. [Lipodystrophic syndromes in HIV-infected patients receiving antiretroviral treatment].
    Simeoni J
    Ann Endocrinol (Paris); 2003 Dec; 64(6):490-1. PubMed ID: 15080164
    [No Abstract]   [Full Text] [Related]  

  • 32. Shifty fat and bad bones (or, in vivo veritas).
    Mascolini M
    IAPAC Mon; 2000 Nov; 6(11):326-50. PubMed ID: 11299996
    [No Abstract]   [Full Text] [Related]  

  • 33. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
    Feleke Y; Fekade D; Mezegebu Y
    Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitochondrial impact of human immunodeficiency virus and antiretrovirals on infected pediatric patients with or without lipodystrophy.
    Morén C; Noguera-Julian A; Rovira N; Corrales E; Garrabou G; Hernández S; Nicolás M; Tobías E; Cardellach F; Miró O; Fortuny C
    Pediatr Infect Dis J; 2011 Nov; 30(11):992-5. PubMed ID: 21697766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complications of HIV disease and antiretroviral therapy.
    Currier JS; Havlir DV
    Top HIV Med; 2005; 13(1):16-23. PubMed ID: 15849369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does atazanavir cause lipodystrophy?
    Gazzard BG; Moyle G
    J HIV Ther; 2004 May; 9(2):41-4. PubMed ID: 15238875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triglyceride increase can predict lipodystrophy in HIV patients under highly active antiretroviral therapy.
    Rodriguez-Guardado A; Maradona JA; Carton JA; Asensi V
    AIDS; 2002 Jul; 16(10):1434-6. PubMed ID: 12131227
    [No Abstract]   [Full Text] [Related]  

  • 38. Complications of HIV disease and antiretroviral therapy.
    Havlir DV; Currier JS
    Top HIV Med; 2006; 14(1):27-35. PubMed ID: 16641525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy.
    Resino S; Micheloud D; Lorente R; Bellon JM; Navarro ML; Munoz-Fernandez MA
    HIV Med; 2011 Jan; 12(1):54-60. PubMed ID: 20497248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Award of the 2003 AIDS Prize. Why doesn HAART therapy induce lipodystrophy in HIV positive patients?].
    HNO; 2003 Jul; 51(7):543. PubMed ID: 12916494
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.